RPA2

Across TCGA pan-cancer cohorts, RPA2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of RPA2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where RPA2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RPA2 is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

CCRCC, COAD, and PDAC are the cancer types where RPA2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPA2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	+0.406	<.001	12	view →
COAD	All	All	+0.144	<.001	8	view →
PDAC	Male	All	+0.464	<.001	6	view →
HNSC	Female	All	−0.190	.044	5	view →
LSCC	Male	II,III,IV	+0.155	<.001	4	view →
OV	All	All	+0.506	.002	2	view →
LUAD	Female	All	+0.108	.019	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

RPA2–CCRCC

Open the CCRCC breakdown →